| 中文名称 |
Opiranserin hydrochloride
|
| 英文名称 |
Opiranserin hydrochloride
|
| 英文别名 |
4-butoxy-N-[[4-(dimethylamino)oxan-4-yl]methyl]-3,5-dimethoxybenzamide;hydrochloride
4-butoxy-N-[[4-(dimethylamino)oxan-4-yl]methyl]-3,5-dimethoxybenzamide
|
| Cas No. |
1440796-75-7
|
| 分子式 |
C21H35ClN2O5
|
| 分子量 |
430.97
|
| 包装储存 |
Powder -20°C 3 years;4°C 2 years
|
| 详情描述 |
Opiranserin (VVZ-149) hydrochloride,一种非阿片类药物和非甾体抗炎止痛药,是 2 型甘氨酸转运蛋白 (GlyT2) 和 5-羟色胺受体2A (5HT2A) 的双重拮抗剂,IC50 分别为 0.86 和 1.3 μM。Opiranserin hydrochloride 对 rP2X3 有拮抗作用 (IC50=0.87 μM)。Opiranserin hydrochloride 可用于术后疼痛的研究。
|
| 产品详情 |
Opiranserin (VVZ-149) hydrochloride,一种非阿片类药物和非甾体抗炎止痛药,是 2 型甘氨酸转运蛋白 (GlyT2) 和 5-羟色胺受体2A (5HT2A) 的双重拮抗剂,IC50 分别为 0.86 和 1.3 μM。Opiranserin hydrochloride 对 rP2X3 有拮抗作用 (IC50=0.87 μM)。Opiranserin hydrochloride 可用于术后疼痛的研究。
|
| 生物活性 |
Opiranserin (VVZ-149) hydrochloride, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC 50 s of 0.86 and 1.3 μM, respectively. Opiranserin hydrochloride shows antagonistic activity on rP2X3 (IC 50 =0.87 μM). Opiranserin hydrochloride is development as an injectable agent for the treatment of postoperative pain.
|
| 性状 |
Solid
|
| IC50 & Target[1][2] |
GlyT2 0.86 μM (IC50) 5-HT2A Receptor
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Powder -20°C 3 years;4°C 2 years
|
| ClinicalTrial |
|
| 参考文献 |
[1]. Oh J, et al. Safety, Tolerability, and Pharmacokinetic Characteristics of a Novel Nonopioid Analgesic, VVZ-149 Injections in Healthy Volunteers: A First-in-Class, First-in-Human Study. J Clin Pharmacol. 2018 Jan;58(1):64-73.[2]. Nedeljkovic SS, et al. Randomised, double-blind, parallel group, placebo-controlled study to evaluate the analgesic efficacy and safety of VVZ-149 injections for postoperative pain following laparoscopic colorectal surgery. BMJ Open. 2017 Feb 17;7(2):e011
|
| 溶解度数据 |
In Vitro: DMSO : 50 mg/mL (116.02 mM; Need ultrasonic)配制储备液
|
[1]. Oh J, et al. Safety, Tolerability, and Pharmacokinetic Characteristics of a Novel Nonopioid Analgesic, VVZ-149 Injections in Healthy Volunteers: A First-in-Class, First-in-Human Study. J Clin Pharmacol. 2018 Jan;58(1):64-73.[2]. Nedeljkovic SS, et al. Randomised, double-blind, parallel group, placebo-controlled study to evaluate the analgesic efficacy and safety of VVZ-149 injections for postoperative pain following laparoscopic colorectal surgery. BMJ Open. 2017 Feb 17;7(2):e011
1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。
2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。